Sepsis Diagnostics Market Growth Fueled by Faster Pathogen Detection Needs

The global sepsis diagnostics market is projected to grow from USD 0.83 billion in 2026 to USD 1.22 billion by 2031, representing a compound annual growth rate (CAGR) of 7.9%. This growth is being driven by the high incidence of sepsis and bloodstream infections, increased adoption of rapid molecular and syndromic diagnostics, broader use of biomarker-based testing, and rising demand for faster pathogen identification and treatment decision support.

These are the latest findings of MarketsandMarkets (Delray Beach, FL, USA), a management consulting firm.

Increasing focus on antimicrobial stewardship is also supporting demand for diagnostic tools that can help clinicians select, adjust, or discontinue antimicrobial therapy more quickly. Blood culture systems, molecular diagnostic platforms, immunoassays, antimicrobial susceptibility testing, mass spectrometry, and clinical chemistry-based tests all play important roles in sepsis diagnosis and patient management. The growing need to reduce delays in treatment decisions is expected to continue supporting adoption of automated and rapid diagnostic technologies.

Based on product, assays, kits, and reagents accounted for the largest share of the global sepsis diagnostics market in 2025, representing 40.7% of revenue. This segment is supported by recurring use across blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Demand for pathogen detection kits, sepsis biomarker assays, PCR-based reagents, and syndromic testing panels is expected to continue supporting the segment’s leading position.

By technology, blood culture and microbiology testing accounted for the largest share of the sepsis diagnostics market in 2025, reflecting their established role in detecting bloodstream infections and supporting antimicrobial susceptibility testing. Molecular diagnostics is expected to grow strongly during the forecast period, driven by increasing adoption of PCR, multiplex PCR panels, sequencing, and other methods that enable faster pathogen identification and resistance marker detection.

By pathogen type, bacterial sepsis held the largest market share in 2025, supported by the high burden of bacterial bloodstream infections, hospital-acquired infections, and ICU-related infections. Laboratory tests accounted for the largest share by test type, while point-of-care tests are expected to grow rapidly as hospitals seek faster sepsis screening and decentralized decision support in emergency and critical care settings. Whole blood remained the leading sample type, given its central role in blood culture testing and molecular pathogen detection.

Hospitals and specialty clinics dominated the market in 2025, accounting for 62.7% of revenue, driven by the high sepsis burden in emergency departments, ICUs, inpatient wards, and critical care settings. Geographically, North America held the largest regional share in 2025 at 43.2%, supported by advanced hospital infrastructure, strong antimicrobial stewardship initiatives, and high adoption of automated blood culture systems and molecular diagnostics. Asia Pacific is expected to record the fastest growth, driven by rising healthcare expenditure, expanding hospital infrastructure, and increasing adoption of automated and molecular diagnostic platforms.

Related Links
MarketsandMarkets